TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06217939
Drug: Normal saline placebo
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.
Study: NCT05220722
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 doses will be delivered via HAI using the PEDD method of administration.
Study: NCT06106685
Drug: Low-dose washed microbiota suspension
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The low-dose group will be administered a low dose of washed microbiota suspension.
Study: NCT04657679
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
Study: NCT05767515
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
Study: NCT05523765
Drug: Brepocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Brepocitinib
Study: NCT05773846
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A long acting formulation of ropivacaine
Study: NCT04938752
Drug: DA-2811
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT00026624
Drug: Keyhole-Limpet Hemocyanin
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04502394
Drug: acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
Study: NCT05330429
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05330429
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05330429
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05447507
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
Study: NCT05447507
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
Study: NCT05507515
Drug: ONO-2020
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-2020 tablets
Study: NCT04749368
Drug: BRII-835 (VIR-2218)
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-835 (VIR-2218) will be given by subcutaneous injection
Study: NCT00133458
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06399068
Drug: CKD-387
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Tablet
Study: NCT06399068
Drug: D484
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 Tablet
Study: NCT05985590
Drug: BMS-986278
Normalized name: BMS-986278
DrugBank: BMS-986278 (DB18011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04530149
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
Study: NCT04530149
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
Study: NCT05193292
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, iv, 21d for a treatment cycle
Study: NCT05193292
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
Study: NCT01254006
Drug: forskolin, rutin and vitamins B1 and B2
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06238349
Drug: Oral bifidobacterium triple live powder
Normalized name: Bifidobacterium bifidum Oral Powder
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
Study: NCT04303325
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
Study: NCT04303325
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
Study: NCT05458492
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks
Study: NCT05297552
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Study: NCT05384691
Drug: Luspatercept Injection
Normalized name: luspatercept Injection
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months.
Study: NCT05280223
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
Study: NCT05264168
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any rivaroxaban dispensing claim is used as the reference group
Study: NCT05264168
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Any apixaban dispensing claim is used as the exposure group
Study: NCT06427863
Drug: Ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study: NCT05235906
Drug: Surufatinib+Sintilimab
Normalized name: Sintilimab
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
Study: NCT00319293
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06600477
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg
Study: NCT05402111
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
Study: NCT05402111
Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Normalized name: Priorix
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study: NCT06136351
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
Study: NCT06136351
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Study: NCT06136351
Drug: Bendamustin
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90mg/m\^2 ivgtt, D0 of each 28-day cycle
Study: NCT06704555
Drug: Tiselizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg iv day 1
Study: NCT06704555
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 intravenous \[IV\] day 2
Study: NCT06704555
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
Study: NCT06704555
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg oral days 3-7
Study: NCT05493969
Drug: Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
Study: NCT05848531
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
Study: NCT03245424
Drug: ivosidenib (AG-120)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
Study: NCT06258772
Drug: Mepolizumab Auto-Injector
Normalized name: mepolizumab Auto-Injector
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab 100 mg in pre-filled injector
Study: NCT05648006
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
Study: NCT05790499
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
Study: NCT05839899
Drug: Mifepristone plus one dose Misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
Study: NCT05839899
Drug: Mifepristone plus two doses Misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
Study: NCT05488327
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
Study: NCT04965272
Drug: Cariprazine 0.75 mg/day
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04965272
Drug: Cariprazine 1.5 mg/day
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04965272
Drug: Cariprazine 3.0 mg/day
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05621499
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg，iv，d1，q3w，a total of 3 cycles
Study: NCT05621499
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 or 8mg/kg，po，qd，a total of 3 cycles
Study: NCT00000642
Drug: CD4-IgG
Normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05686629
Drug: Jaktinib hydrochloride tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses per day, each containing two 50mg Jaktinib or placebo tablets
Study: NCT03778424
Drug: Rufinamide
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
Study: NCT06077721
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
Study: NCT00006493
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000662
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05027594
Drug: NMS-03597812
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
Study: NCT05027594
Drug: NMS-03597812 + dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
Study: NCT04764006
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
Study: NCT06117644
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib 40 mg/tablet, 4 tablets, QD
Study: NCT00337740
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05243940
Drug: dexmedetomidine-ketamine-lidocaine (DKL)
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution.
Study: NCT05791669
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
Study: NCT05791669
Drug: Sodium fluoride varnish
Normalized name: Sodium Fluoride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
Study: NCT06352502
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with Furmonertinib mesilate tablets orally
Study: NCT05608213
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
Study: NCT05862753
Drug: induction by Etomidate bolus
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
Study: NCT05687058
Drug: Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session under direct observation by a trained health care worker.
Study: NCT05687058
Drug: Empagliflozin 10 mg daily dosing
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
Study: NCT04900766
Drug: Mitoxantrone Hydrochloride Liposome Injection
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Study: NCT06674538
Drug: Moonshot antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chimeric antibodies
Study: NCT06676683
Drug: Usage of Statin in diabetic patients
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The use of statin in diabetic patients not known to have Atherosclerotic cardiovascular disease in a low income community
Study: NCT05546957
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally once per day (QD)
Study: NCT05546957
Drug: rivaroxaban low dose
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally twice per day (BID)
Study: NCT05546957
Drug: rivaroxaban high dose
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally QD
Study: NCT00290069
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04734249
Drug: Surufatinib(HMPL-012)
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC.
Study: NCT06425224
Drug: Dapoxetine placebo
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
Study: NCT06435455
Drug: GH21
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
Study: NCT06435455
Drug: D-1553
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
Study: NCT04851522
Drug: Di-Dak-Sol
Normalized name: Di-Dak-Sol
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution applied externally.
Study: NCT00304681
Drug: OROS*-Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04949503
Drug: nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
Study: NCT00000980
Drug: Spiramycin
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT04156984
Drug: Golimumab Prefilled Syringe
Normalized name: golimumab Prefilled Syringe
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: See arm description